F. Stoll

The chemistry and biology of soluble guanylate cyclase stimulators and activators.

J. Stasch, M. Schäfer, F. Mais, 2013, Angewandte Chemie.

Utility of protein structures in overcoming ADMET-related issues of drug-like compounds.

Alexander Hillisch, Andreas H Göller, A. Göller, 2011, Drug discovery today.

Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists.

Hans-Dieter Höltje, Thomas Hohlfeld, K. Schrör, 2002, Molecular pharmacology.

Identification of residues crucially involved in soluble guanylate cyclase activation

J. Stasch, H. Schröder, Christiane Rothkegel, 2006, FEBS letters.

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia

J. Keldenich, Hans-Christian Militzer, I. Flamme, 2018, ChemMedChem.

Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context.

Holger Gohlke, Nadine Homeyer, Alexander Hillisch, 2014, Journal of chemical theory and computation.

Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection.

Peter Meier, Pierre Acklin, Kamal Azzaoui, 2005, Current topics in medicinal chemistry.